Angiotech's Corporate Partner, Boston Scientific, announces Japanese approval for the TAXUS(R) Express2(TM) stent system

    VANCOUVER, April 3 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, along
with its corporate partner, Boston Scientific Corporation (NYSE:   BSX),
announced today that Boston Scientific has received approval from the Japanese
Ministry of Health, Labour and Welfare (MHLW) to market its TAXUS(R)
Express2(TM) paclitaxel-eluting coronary stent system in Japan. Boston
Scientific plans to launch the product upon receipt of reimbursement approval.
    "We are pleased that the proven technology of the TAXUS Express2 stent is
now available to Japanese physicians, which will help improve the quality of
life for so many patients," said Dr. William Hunter, President and CEO of

    Note on Forward Looking Statements
    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from any future results, events or developments
expressed or implied by such forward-looking statements. Many such risks,
uncertainties and other factors are taken into account as part of our
assumptions underlying these forward-looking statements and include, among
others, the following; general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or our ability
to develop and commercialize future products; competition; existing
governmental regulations and changes in, or the failure to comply with,
governmental regulations; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products
and decisions regarding reimbursement where applicable; the requirement for
substantial funding to conduct research and development and to expand
commercialization activities; and any other factors that may affect
performance. In addition, our business is subject to certain operating risks
that may cause the actual results expressed or implied by the forward-looking
statements in this report to differ materially from our actual results. These
operating risks include; poor performance of the product in the clinical
setting; adverse events related to the use of the product; improper estimation
of the size of the product markets; adverse results or unexpected delays in
clinical development processes; our ability to attract and retain qualified
personnel; our ability to successfully complete preclinical and clinical
development of our products; changes in business strategy or development
plans; our failure to obtain patent protection for discoveries; loss of patent
protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by third
parties; our ability to obtain rights to technology from licensors; liability
for patent claims and other claims asserted against us; our ability to obtain
and enforce timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to maintain, corporate
alliances relating to the development and commercialization of our technology
and products; market acceptance of our technology and products; our ability to
successfully manufacture, market and sell our products; the continued
availability of capital to finance our activities; our ability to continue to
integrate into our business the operations of American Medical Instruments
Holdings, Inc. and our ability to achieve the operational and other synergies
and the other commercial or financial benefits expected as a result of that
acquisition; and any other factors referenced in our annual information form
and other filings with the applicable Canadian securities regulatory
authorities or the SEC.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements. We
disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained in
this prospectus to reflect future results, events or developments.

    (R), (TM) Trademarks of Boston Scientific Corporation

    About Angiotech
    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with 17 facilities in 6 countries and over 1,500
dedicated employees. Angiotech discovers, develops and markets innovative
treatment solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find out more
about Angiotech (NASDAQ:   ANPI, TSX: ANP), please visit our website at

For further information:

For further information: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-6933,; Jodi Regts, Manager, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890